Synergistic Combination Therapies for Progeroid Diseases and Conditions
Legal Citation
Summary of the Inventive Concept
This inventive concept integrates the original patented combination therapies for progeroid diseases and conditions with cutting-edge technologies such as AI, IoT, blockchain, and new materials to create a more powerful system for treating and managing these diseases.
Background and Problem Solved
The original patented combination therapies for progeroid diseases and conditions, cellular aging, and atherosclerosis demonstrated promising results. However, there was a need to further enhance the treatment efficacy and patient outcomes by leveraging the capabilities of emerging technologies. This inventive concept addresses this limitation by synergistically combining the original therapies with distinct technologies to create a more comprehensive and effective system.
Detailed Description of the Inventive Concept
The new system comprises a combination therapy module that integrates a farnesyltransferase inhibitor with an mTOR inhibitor, and a blockchain-based tracking system for monitoring treatment efficacy. Additionally, the system incorporates AI-powered algorithms for personalized treatment planning, IoT-enabled health record systems for seamless data integration, and 3D printing technology for customized bone implants. The system's components work in tandem to provide a holistic approach to treating progeroid diseases and conditions, cellular aging, and atherosclerosis.
Novelty and Inventive Step
The novelty of this inventive concept lies in the synergistic integration of the original patented combination therapies with distinct technologies such as AI, IoT, blockchain, and new materials. The inventive step is the unexpected improvement in treatment efficacy and patient outcomes achieved by combining these technologies in a single system.
Alternative Embodiments and Variations
Alternative embodiments of this inventive concept could include the use of different AI algorithms, varying blockchain architectures, or the integration of additional emerging technologies such as nanotechnology or bioprinting. Variations of the system could also be tailored to specific disease conditions or patient populations.
Potential Commercial Applications and Market
This inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the areas of personalized medicine and regenerative therapies. The target market includes pharmaceutical companies, research institutions, and healthcare providers seeking to improve treatment outcomes for progeroid diseases and conditions.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Medical therapeutics and biotechnology, specifically focused on treatment of progeroid diseases, cellular aging, and cardiovascular conditions. Expertise would include pharmacology, molecular biology, drug combination strategies, and emerging medical technologies
Person of Ordinary Skill (PHOSITA) Profile
A medical researcher or clinical pharmacologist with advanced degree (PhD/MD), understanding of molecular pathways in aging and disease, familiarity with combination therapies, and working knowledge of emerging medical technologies
Obviousness Rationale
A PHOSITA would recognize that integrating digital technologies with established pharmaceutical combination therapies represents a natural progression in personalized medicine. The blockchain, AI, and IoT technologies proposed are well-established in medical informatics and provide predictable enhancements to treatment monitoring and personalization. The core pharmaceutical combination of farnesyltransferase and mTOR inhibitors remains consistent with the source patent's fundamental therapeutic approach.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,541 |
|---|---|
| Title | Combination therapies for treatment of laminopathies, cellular aging, and atherosclerosis |